Ensysce Biosciences (ENSC)
NASDAQ:ENSC
Total Valuation
Ensysce Biosciences has a market cap or net worth of $5.66M. The enterprise value is -$4.00T.
Market Cap$5.66M
Enterprise Value-$4.00T
Share Statistics
Ensysce Biosciences has 9,277,819 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding9,277,819
Owned by Insiders―
Owned by Institutions11.38%
Financial Efficiency
Ensysce Biosciences’s return on equity (ROE) is -3.17 and return on invested capital (ROIC) is -320.89%.
Return on Equity (ROE)-3.17
Return on Assets (ROA)-1.37
Return on Invested Capital (ROIC)-320.89%
Return on Capital Employed (ROCE)-3.55
Revenue Per Employee0.00
Profits Per Employee-1.45T
Employee Count7
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Ensysce Biosciences is ―. Ensysce Biosciences’s PEG ratio is <0.00001.
PE Ratio―
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF>-0.01
Price to Operating Cash Flow-0.20
PEG Ratio<0.00001
Income Statement
In the last 12 months, Ensysce Biosciences had revenue of 0.00 and earned -10.18T in profits. Earnings per share was -3.98.
Revenue0.00
Gross Profit0.00
Operating Income-10.24T
Pretax Income-10.18T
Net Income-10.18T
EBITDA-10.15M
Earnings Per Share (EPS)-3.98
Cash Flow
In the last 12 months, operating cash flow was -7.81M and capital expenditures -123.64K, giving a free cash flow of -7.93M billion.
Operating Cash Flow-7.81M
Free Cash Flow-7.93M
Free Cash Flow per Share-0.85
Dividends & Yields
Ensysce Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.90
52-Week Price Change-69.55%
50-Day Moving Average0.55
200-Day Moving Average1.58
Relative Strength Index (RSI)57.29
Average Volume (3m)89.63K
Important Dates
Ensysce Biosciences upcoming earnings date is May 18, 2026, After Close (Confirmed).
Last Earnings DateMar 30, 2026
Next Earnings DateMay 18, 2026
Ex-Dividend Date―
Financial Position
Ensysce Biosciences as a current ratio of 1.59, with Debt / Equity ratio of 9543706.36%
Current Ratio1.59
Quick Ratio1.59
Debt to Market Cap130.38K
Net Debt to EBITDA394.41K
Interest Coverage Ratio-545.69M
Taxes
In the past 12 months, Ensysce Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Ensysce Biosciences EV to EBITDA ratio is 394.41K, with an EV/FCF ratio of 0.51.
EV to Sales0.00
EV to EBITDA394.41K
EV to Free Cash Flow0.51
EV to Operating Cash Flow0.51
Balance Sheet
Ensysce Biosciences has $4.31T in cash and marketable securities with $306.71B in debt, giving a net cash position of $4.00T billion.
Cash & Marketable Securities$4.31T
Total Debt$306.71B
Net Cash$4.00T
Net Cash Per Share$431.53K
Tangible Book Value Per Share$1.13M
Margins
Gross margin is -53.19%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-53.19%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Ensysce Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast1.51%
EPS Growth Forecast77.64%